Courante Oncology was originally named Onyx Oncology. Onyx was founded in 1999 by Jill DeLosh, an independent consultant in the pharmaceutical industry. After losing both parents to cancer, Jill focused her work in oncology. As president of Onyx, Jill recruited other independent consultants who were equally dedicated to her mission. In March of 2003, we lost Jill to cancer. One of her wishes was to have the work she started continue. Jill’s battle with cancer continues to serve as an inspiration to us.
As the current president of Courante Oncology, Sheri Smith continues the work Jill started. Sheri brings nearly two decades of drug development experience to assist you and your clinical team with product registration and market support.
Sheri has spent the past 15 years specializing in the development of both therapeutic and supportive care oncology products. As the former Senior Director of Clinical Operations at MGI PHARMA, Inc, she oversaw the conduct of multinational clinical trials and was responsible for clinical research, data management, database, statistical, and clinical documentation work groups.
Prior to her work in oncology, Sheri managed and monitored phase I-IV trials in a variety of indications for Abbott Laboratories and 3M Pharmaceuticals. During that time she prepared key clinical and statistical sections for two new drug applications (NDAs) and a supplemental NDA. Sheri received her Bachelor of Arts in Biology from St. Olaf College in Northfield, MN, and her Master of Science in Statistics from Iowa State University.